107 related articles for article (PubMed ID: 28847671)
1. Erlotinib-loaded albumin nanoparticles: A novel injectable form of erlotinib and its in vivo efficacy against pancreatic adenocarcinoma ASPC-1 and PANC-1 cell lines.
Noorani M; Azarpira N; Karimian K; Heli H
Int J Pharm; 2017 Oct; 531(1):299-305. PubMed ID: 28847671
[TBL] [Abstract][Full Text] [Related]
2. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
[TBL] [Abstract][Full Text] [Related]
3. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
4. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid.
Dora CP; Kushwah V; Katiyar SS; Kumar P; Pillay V; Suresh S; Jain S
Int J Pharm; 2017 Dec; 534(1-2):1-13. PubMed ID: 28970115
[TBL] [Abstract][Full Text] [Related]
5. Redox responsive albumin autogenic nanoparticles for the delivery of cancer drugs.
Thirupathi Kumara Raja S; Prakash T; Gnanamani A
Colloids Surf B Biointerfaces; 2017 Apr; 152():393-405. PubMed ID: 28157647
[TBL] [Abstract][Full Text] [Related]
6. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
[TBL] [Abstract][Full Text] [Related]
7. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization and cytotoxic evaluation of bovine serum albumin nanoparticles encapsulating 5-methylmellein: A secondary metabolite isolated from Xylaria psidii.
Arora D; Kumar A; Gupta P; Chashoo G; Jaglan S
Bioorg Med Chem Lett; 2017 Dec; 27(23):5126-5130. PubMed ID: 29100800
[TBL] [Abstract][Full Text] [Related]
9. Preparation of DOX/BSANP and its antitumor effect on bel-7404 liver cancer cells in vitro and in vivo.
Miao FQ; An YL; Yang R; Tang QS; Zhang JQ
Biomed Mater Eng; 2014; 24(1):599-607. PubMed ID: 24211944
[TBL] [Abstract][Full Text] [Related]
10. ATP-loaded biomimetic nanoparticles as controlled release system for extracellular drugs in cancer applications.
Díaz-Saldívar P; Huidobro-Toro JP
Int J Nanomedicine; 2019; 14():2433-2447. PubMed ID: 31040666
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy.
Cui M; Naczynski DJ; Zevon M; Griffith CK; Sheihet L; Poventud-Fuentes I; Chen S; Roth CM; Moghe PV
Adv Healthc Mater; 2013 Sep; 2(9):1236-45. PubMed ID: 23495216
[TBL] [Abstract][Full Text] [Related]
12. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
[TBL] [Abstract][Full Text] [Related]
13. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability.
Dora CP; Trotta F; Kushwah V; Devasari N; Singh C; Suresh S; Jain S
Carbohydr Polym; 2016 Feb; 137():339-349. PubMed ID: 26686138
[TBL] [Abstract][Full Text] [Related]
14. A comparative study on the effect of docetaxel-albumin nanoparticles and docetaxel-loaded PEG-albumin nanoparticles against non-small cell lung cancer.
Jin G; Jin M; Yin X; Jin Z; Chen L; Gao Z
Int J Oncol; 2015 Nov; 47(5):1945-53. PubMed ID: 26398837
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway.
Jiang J; Yuan Z; Sun Y; Bu Y; Li W; Fei Z
Biomed Pharmacother; 2017 Dec; 96():619-625. PubMed ID: 29035827
[TBL] [Abstract][Full Text] [Related]
17. Development of albumin-based nanoparticles for the delivery of abacavir.
Wilson B; Paladugu L; Priyadarshini SR; Jenita JJ
Int J Biol Macromol; 2015 Nov; 81():763-7. PubMed ID: 26365020
[TBL] [Abstract][Full Text] [Related]
18. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug.
Battogtokh G; Kang JH; Ko YT
Eur J Pharm Biopharm; 2015 Oct; 96():96-105. PubMed ID: 26212785
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles based on albumin: preparation, characterization and the use for 5-flurouracil delivery.
Wilson B; Ambika TV; Patel RD; Jenita JL; Priyadarshini SR
Int J Biol Macromol; 2012 Dec; 51(5):874-8. PubMed ID: 22820011
[TBL] [Abstract][Full Text] [Related]
20. Carrier-Free Nanoassembly of Curcumin-Erlotinib Conjugate for Cancer Targeted Therapy.
Cheng C; Sui B; Wang M; Hu X; Shi S; Xu P
Adv Healthc Mater; 2020 Oct; 9(19):e2001128. PubMed ID: 32893507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
